PHARMACEUTICAL COMPOSITION

WIPO Patent Application WO/2016/148260

A1

Provided is a therapeutic and/or prophylactic agent or the like for early-stage Parkinson's disease which includes, as active ingredients, istradefylline (A), L-DOPA (B), and a dopamine agonist (C), and which is characterized in that the istradefylline (A), the L-DOPA (B), and the dopamine agonist (C) are each administered simultaneously or separately at intervals.

JP3176633	[Title of Invention] Guanine derivative
WO/2008/151415	COMBINATION FOR TREATMENT OF DIABETES MELLITUS
JP2022058416	METHODS AND COMPOSITIONS FOR TREATING HERPESVIRUS-INDUCED CONDITIONS

KANDA TOMOYUKI (JP)
UCHIDA SHIN-ICHI (JP)

PCT/JP2016/058591

September 22, 2016

March 17, 2016

Click for automatic bibliography generation  

KYOWA HAKKO KIRIN CO LTD (JP)

A61K31/522; A61K31/198; A61K31/4045; A61K31/48; A61K45/00; A61P25/16; A61P43/00

JP2005523898A	2005-08-11
JPH06211856A	1994-08-02

UCHIDA,S. ET AL.: "The adenosine A2A receptor antagonist, istradefylline enhances the anti- parkinsonian activity of low doses of dopamine agonists in MPTP-treated common marmosets", EUROPEAN JOURNAL OF PHARMACOLOGY, vol. 747, 15 January 2015 (2015-01-15), pages 160 - 165, XP029189900, ISSN: 0014-2999
UCHIDA,S. ET AL.: "The adenosine A2A receptor antagonist, istradefylline enhances anti- parkinsonian activity induced by combined treatment with low doses of L-DOPA and dopamine agonists in MPTP-treated common marmosets", EUROPEAN JOURNAL OF PHARMACOLOGY, vol. 766, 5 November 2015 (2015-11-05), pages 25 - 30, XP055312240, ISSN: 0014-2999

View/Download PDF      PDF Help

Previous Patent: STRUCTURAL MEMBER AND CORE MATERIAL

Next Patent: THERAPEUTIC AND/OR PROPHYLACTIC AGENT FOR LEWY BODY DISEASES